Pharmacological inhibition of protein tyrosine phosphatase 1B protects against atherosclerotic plaque formation in the LDLR−/− mouse model of atherosclerosis
Open Access
- 29 September 2017
- journal article
- Published by Portland Press Ltd. in Clinical Science
- Vol. 131 (20) , 2489-2501
Abstract
Cardiovascular disease (CVD) is the most prevalent cause of mortality among patients with type 1 or type 2 diabetes, due to accelerated atherosclerosis. Recent evidence suggests a strong link between atherosclerosis and insulin resistance, due to impaired insulin receptor (IR) signalling. Here, we demonstrate that inhibiting the activity of protein tyrosine phosphatase 1B (PTP1B), the major negative regulator of the IR prevents and reverses atherosclerotic plaque formation in an LDLR−/− mouse model of atherosclerosis. Acute (single dose) or chronic PTP1B inhibitor (trodusquemine) treatment of LDLR−/− mice decreased weight gain and adiposity, improved glucose homeostasis and attenuated atherosclerotic plaque formation. This was accompanied by a reduction in both, circulating total cholesterol and triglycerides, a decrease in aortic monocyte chemoattractant protein-1 (MCP-1) expression levels and hyperphosphorylation of aortic Akt/PKB and AMPKα. Our findings are the first to demonstrate that PTP1B inhibitors could be used in prevention and reversal of atherosclerosis development and reduction in CVD risk.Keywords
This publication has 39 references indexed in Scilit:
- Thrombosis formation on atherosclerotic lesions and plaque ruptureJournal of Internal Medicine, 2014
- Akt2/LDLr double knockout mice display impaired glucose tolerance and develop more complex atherosclerotic plaques than LDLr knockout miceCardiovascular Research, 2013
- PTP1B in the Periphery: Regulating Insulin Sensitivity and ER Stress2013
- Impact of Diabetes on Cardiovascular Disease: An UpdateInternational Journal of Hypertension, 2013
- Inflammation in AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- Accelerated Atherosclerosis in
Apoe
−/−
Mice Heterozygous for the Insulin Receptor and the Insulin Receptor Substrate-1Arteriosclerosis, Thrombosis, and Vascular Biology, 2012
- Apolipoprotein B Secretion Is Regulated by Hepatic Triglyceride, and Not Insulin, in a Model of Increased Hepatic Insulin SignalingArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- Loss of Insulin Signaling in Vascular Endothelial Cells Accelerates Atherosclerosis in Apolipoprotein E Null MiceCell Metabolism, 2010
- Myeloid lineage cell-restricted insulin resistance protects apolipoproteinE-deficient mice against atherosclerosisCell Metabolism, 2006
- Increased Insulin Sensitivity and Obesity Resistance in Mice Lacking the Protein Tyrosine Phosphatase-1B GeneScience, 1999